t(2;19)(p11;p13)

2007-08-01   Jean-Loup Huret 

1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

Acute myeloid leukaemia (AML)

Phenotype stem cell origin

One de novo AML (M2 type), and a therapy related AML (t-AML)

Epidemiology

The de novo AML was a 11 year old girl; the t-AML case was a 58 year old female patient who had been treated for ovary carcinoma with melphalan 1.5 yrs before.

Prognosis

No complete remission (CR) in the de novo case; CR was obtained but a relapse occurred and the patient died 3 months after diagnosis in the therapy related case.

Genes Involved and Proteins

Note
Genes involved are unknown.

Bibliography

Pubmed IDLast YearTitleAuthors
31672101988Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.Larson RA et al

Citation

Jean-Loup Huret

t(2;19)(p11;p13)

Atlas Genet Cytogenet Oncol Haematol. 2007-08-01

Online version: http://atlasgeneticsoncology.org/haematological/1288/t(2;19)(p11;p13)

External Links